Document is current

Any future updates will be listed below

Erster oraler CGRP-Antagonist für die Migräneprophylaxe geht in die Zulassungsphase

Crossref DOI link: https://doi.org/10.1007/s15005-021-2033-2

Published Online: 2021-08-25

Published Print: 2021-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark